Can low-dose azacitidine + venetoclax be used as maintenance therapy in patients with AML in remission after either intensive or low-intensity induction?

Check out our summary of a recent phase II trial here: loom.ly/ndkB_LU

#AMLsm #leusm #leukemia #MedicalEducation

🚨 NEWS 🚨
U.S. FDA grants Orphan Drug Designation to IGNK001, an investigational allogeneic natural killer cell therapy, for the treatment of acute myeloid leukemia.
Read more here 👉 loom.ly/Kq5tl-I
#AMLsm #leusm #leukemia #MedicalEducation #MedNews

Do you intend to implement next generation sequencing for measurable residual disease monitoring in MDS patients?

Is crenolanib plus intensive chemotherapy a feasible treatment option for patients with ND FLT3-AML?

Read our summary of a recent pilot study to learn more: loom.ly/vRr7KGg

#AMLsm #leusm #leukemia #MedicalEducation

Is there a survival benefit from the addition of gemtuzumab ozogamicin to 7 + 3 induction therapy in patients with ND AML and intermediate cytogenetics?
Read more here: loom.ly/FFBAmYs
#AMLsm #leusm #leukemia #MedicalEducation

🎥 #CART24 | The AML Hub spoke to Sarah Tettamanti, Tettamanti Foundation Research Center, Monza, IT. We asked, What are the challenges associated with CAR T-cell therapy in patients with AML?
Watch here: loom.ly/xsCEgMM
#leusm #AMLsm #MedEducation

🚨 NEWS 🚨

U.S. FDA grants Breakthrough Therapy Designation for ziftomenib, a novel therapy that targets the menin-KMT2A/MLL protein-protein interaction, for the treatment of NPM1-mutated AML.

Read more here 👉 loom.ly/Ff8Eh8g

#AMLsm #leusm #leukemia #MedicalEducation

Is automated semiconductor-based NGS viable in AML?

Read our summary of a validation of the Oncomine Myeloid Assay GX v2 in myeloid malignancies here: loom.ly/jP9QrwE

#leusm #AMLsm

The AML Hub is pleased to announce the launch of our Instagram account, aml_hub. Follow us to keep up-to-date with all the latest insights and medical education in Acute Myeloid Leukemia #AML #MedicalEducation #IME

The AML Hub is proud to support #AMLWorldAwarenessDay ! AML World Awareness Day is an important opportunity to unite and raise awareness of AML! 🌏

To learn more, visit: loom.ly/AkyDt8s

#KnowAML

🚨 NEWS 🚨

U.S. FDA grants Orphan Drug Designation to BVX001, a novel twin CD33/CD7 targeting bispecific antibody-drug conjugate, for the treatment of patients with acute myeloid leukemia.

Read more here: loom.ly/HkAMAcI

#AMLsm #leusm #MedNews

🚨 NEWS 🚨

EU Medicines Agency grants Orphan Drug Designation to annamycin, a next-generation anthracycline, for the treatment of patients with acute myeloid leukemia.

Read more here: loom.ly/JBYvTZ4

#MedNews #leusm #AML

Can ivosidenib be used as a single agent targeted therapy in patients with relapsed/refractory AML after allogeneic hematopoietic stem cell transplantation?

Read our summary of a recent retrospective study to learn more: loom.ly/2AgOQJ0

#AMLsm #leusm #leukemia #MedEd

📢 April 21 is #AMLWorldAwarenessDay ! 📢

Let us unite and raise awareness of #AcuteMyeloidLeukemia ! 🌎

Join the collective voice advocating for patients with this cancer.

To learn how to get involved, visit: loom.ly/AkyDt8s

#KnowAML

We hope you enjoyed following our live updates and congress coverage from  #EBMT 24 !

Keep an eye on our socials for post-congress key points and insights.

#IME   #cancerresearch   #EBMT

CONGRESS | #EBMT24
Yanmin Zhao uses data from a multi-center, retrospective cohort study to evaluate the impact of MRD status on CR among patients with FLT3-ITD AML undergoing sorafenib maintenance post-transplantation. MVA associates MR gene mutations with adverse outcomes in OS…

CONGRESS | #EBMT24
Christina Rautenberg from Uniklinikum Essen, discusses if CPX-351 is an efficient treatment for patients with high-risk AML using updated real-world data with an extended 3-year follow-up.
The EBMT #TheEBMT #leusm #MedicalCongress

CONGRESS | #EBMT24
Ali Bazarbachi presents post-transplant outcomes of older patients with AML who received allo-HCT. From MVA, 3-year RI significantly decreased from 37% to 31% and then to 30% (p = 0.001); NRM decreased from 31% and 31% to 27% (p = 0.003).
The EBMT #TheEBMT …

CONGRESS | #EBMT24
Hannah Choe discusses data from the phase III SIERRA study assessing survival outcomes of 131I-apamistamab-led allo-HCT in patients with R/R AML. CR and dCR rates in patients treated with Iomab-B were similar irrespective of TP53 status.
The EBMT #TheEBMT …

CONGRESS | #EBMT24
Arnon Nagler, Arnon Nagler delivers an interesting presentation on the validation of the ICC 2022 classification in AML patients with myelodysplasia-related changes who are undergoing allo-HSCT from the ALWP of the EBMT.
The EBMT #leusm #MedicalCongress